|Systematic (IUPAC) name|
|Legal status||Never marketed|
|Routes||Injection into pleural space or abdomen|
|Mol. mass||477.64 g/mol|
Batimastat (INN/USAN, codenamed BB-94) is an anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. It acts as a matrix metalloproteinase inhibitor (MMPI) by mimicking natural MMPI peptides.
Batimastat was the first MMPI that went into clinical trials. First results of a Phase I trial appeared in 1994. The drug reached Phase III but was never marketed; mainly because it couldn't be administered orally (as opposed to the newer and chemically similar MMPI marimastat), and injection into the peritoneum caused peritonitis.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|